fbpx

Therapeutics

Developing the next generation of IPSCs
Induced pluripotent stem cells therapies

Stem Cell Therapeutics

Pure Medical is developing next-generation IPSC stem cell immunotherapies combining its two proprietary platforms – Immunocell® biotherapeutics and Pluricision® targeted cell therapy. With this approach, the Company aims to address the lack of a durable response to current biological and immunotherapies as well as current high off-target toxicity experienced by most patients.

 

Pure Medical aims to enter the clinic with its lead Immunocell® programme in summer 2022. IPSCs are ethically derived from skin cells that have been reprogrammed back into an embryonic-like pluripotent state that enables the development of an unlimited source of any type of human cell needed for therapeutic purposes. For example, iPSCs can be stimulated into becoming beta islet cells to treat diabetes, blood cells to create new blood free of cancer cells for a leukaemia patient, or neurons to treat neurological disorders.

 

Using iPSC technology our scientists have reprogrammed skin cells into active motor neurons, egg and sperm precursors, liver cells, bone precursors, and blood cells. In addition, patients with untreatable diseases such as ALS, Rett Syndrome, Lesch-Nyhan Disease, and Duchenne’s Muscular Dystrophy donate skin cells to Pure Medical scientists for iPSC reprogramming research. The generous participation of patients and their families in this research enables Pure Medical scientists to study these diseases in the laboratory in the hope of developing new treatment technologies.

 

Pure Medical has established drug development partnerships with pharma and biotech, including a research collaboration with a number of leading universities. The Company is actively seeking commercialisation and collaboration deals with therapeutic companies to license its proprietary platforms in a range of therapeutic areas.
Applications
Pure Medical proprietary Immunocell® biotherapeutics can be developed for a range of applications.

 

Pipeline
Pure Medical has a pre-clinical stage biopharmaceutical pipeline of Immunocell® therapeutic candidates.

 

READ MORE >
Partnerships
Pure Medical works with partners where there is a mutual interest in co-funding a development programme.

 

Become an
Investor in Health
MAKE AN ENQUIRY
Pure Medical is actively seeking partnerships and licensing opportunities. Contact us to make an enquiry.

 

Pure Medical Therapeutics Mobile

Therapeutics

Developing the next generation of IPSCs Induced pluripotent stem cells therapies

Stem Cell Therapeutics

Pure Medical is developing next-generation IPSC stem cell immunotherapies combining its two proprietary platforms – Immunocell® biotherapeutics and Pluricision® targeted cell therapy. With this approach, the Company aims to address the lack of a durable response to current biological and immunotherapies as well as current high off-target toxicity experienced by most patients.

 

Pure Medical aims to enter the clinic with its lead Immunocell® programme in summer 2022. IPSCs are ethically derived from skin cells that have been reprogrammed back into an embryonic-like pluripotent state that enables the development of an unlimited source of any type of human cell needed for therapeutic purposes. For example, iPSCs can be stimulated into becoming beta islet cells to treat diabetes, blood cells to create new blood free of cancer cells for a leukaemia patient, or neurons to treat neurological disorders.

 

Using iPSC technology our scientists have reprogrammed skin cells into active motor neurons, egg and sperm precursors, liver cells, bone precursors, and blood cells. In addition, patients with untreatable diseases such as ALS, Rett Syndrome, Lesch-Nyhan Disease, and Duchenne’s Muscular Dystrophy donate skin cells to Pure Medical scientists for iPSC reprogramming research. The generous participation of patients and their families in this research enables Pure Medical scientists to study these diseases in the laboratory in the hope of developing new treatment technologies.

 

Pure Medical has established drug development partnerships with pharma and biotech, including a research collaboration with a number of leading universities. The Company is actively seeking commercialisation and collaboration deals with therapeutic companies to license its proprietary platforms in a range of therapeutic areas.
Applications
Pure Medical proprietary Immunocell® biotherapeutics can be developed for a range of applications.

 

Pipeline
Pure Medical has a pre-clinical stage biopharmaceutical pipeline of Immunocell® therapeutic candidates.

 

READ MORE >
Partnerships
Pure Medical works with partners where there is a mutual interest in co-funding a development programme.

 

Become an
Investor in Health
MAKE AN ENQUIRY
Pure Medical is actively seeking partnerships and licensing opportunities. Contact us to make an enquiry.

 

Pure Medical Therapeutics Mobile Footer